TrialNerd_Beth said:Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent…
No disagreement with TrialNerd_Beth. One condition attached. Yes, and the corollary is less popular: if the reasoning holds, it also holds where it produces an answer we do not like.
NauseaFreeNow said:NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy.
Saving this. It is the first explanation that did not require me to already understand it. Taking it to my next appointment.
TrialNerd_Beth said:Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent…
Pushing back on TrialNerd_Beth here. This treats a plausible mechanism as a demonstrated one. Plausible is where you start looking, not where you stop.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOne concrete data point for the thread. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.